

INFORMAZIONI GENERALI

SEDE

I Portici Hotel Via Indipendenza 69 - 40121 Bologna

MODALITÀ DI PARTECIPAZIONE

Questo evento formativo si terrà esclusivamente in forma residenziale



ISCRIZIONI

L'iscrizione al corso è gratuita, potrà avvenire esclusivamente attraverso procedura online sul nostro sito: www.mitcongressi.it selezionando il corso dal catalogo.

Non sarà garantita la possibilità di iscriversi presso la sede congressuale

INFO ECM

Il corso è stato accreditato in modalità RES (Formazione residenziale)

N. ECM 1509-XXXXX - Ore X - Crediti X

Professioni accreditate: XXXXX

ISTRUZIONI ECM

A conclusione del corso, Questionario ECM e Attestato di Partecipazione saranno disponibili online accedendo alla nostra piattaforma formazione.mitcongressi.it nella sezione "I miei corsi" della propria area riservata. Ai fini dell'acquisizione dei crediti formativi è INDISPENSABILE la presenza effettiva al 90% della durata complessiva dei lavori e il raggiungimento di almeno il 75% delle risposte corrette al questionario di valutazione dell'apprendimento. La compilazione del questionario darà diritto ai crediti SOLO se associata alla verifica dell'effettiva presenza all'evento e alla compilazione contestuale del questionario di gradimento del corso. La scadenza per la compilazione del questionario di valutazione ECM e del questionario di gradimento del corso è fissata entro le 72 ore dalla fine del corso.

SEGRETERIA ORGANIZZATIVA - PROVIDER N.1509



MI&T srl Centro Direzionale Bolomnina Via Guelfa 5 - 40138 Bologna

www.mitcongressi.it

CON IL CONTRIBUTO INCONDIZIONATO DI:

PLATINUM



novocure®

GOLD



SILVER

CARTHERA
Advanced Brain Therapy

CHIMERIX

SERVIER
moved by you

27 SETTEMBRE 2024
BOLOGNA I Portici Hotel

NEW APPROACHES IN BRAIN TUMORS

CHAIRMAN
ENRICO FRANCESCHI

Brain tumors continue to present significant challenges in terms of diagnosis, treatment, and management. However, there have been notable advancements and new approaches in recent years aimed at improving outcomes for patients. Given the complex nature of brain tumors and the challenges associated with treatment resistance, researchers are exploring combination therapies that target multiple pathways involved in tumor growth and progression. Combinations of chemotherapy, targeted therapy, immunotherapy, and other modalities are being investigated to improve treatment outcomes and overcome resistance mechanisms. These new approaches reflect the multidisciplinary efforts to advance the field of brain tumor treatment and ultimately improve patient outcomes. There's been a growing emphasis on precision medicine also in the treatment of brain tumors.

This approach involves tailoring treatment based on the specific genetic makeup of the tumor and the patient. Advances in genomic sequencing and molecular profiling have enabled clinicians to identify specific mutations and biomarkers that can guide targeted therapies.

Immunotherapy has emerged as a promising treatment modality in different cancer types. This approach harnesses the body's immune system to target and destroy cancer cells. Checkpoint inhibitors, chimeric antigen receptor (CAR) T-cell therapy, and other immunotherapeutic strategies are being investigated in clinical trials for brain tumors.

Non pharmaceutical approaches are also in development. Focused ultrasounds, tumor-treating fields, new radiotherapy techniques, cellular therapies are under development to enhance the clinical possibilities for brain tumor patients. Continued research and collaboration will be essential in further refining these approaches and translating them into clinical practice.

This course will focus on new approaches in brain tumors, given on the clinical significance of the condition, the rapidly evolving nature of the field, the interdisciplinary collaboration required for effective management, the need for patient-centered care, the presence of unmet needs, the educational gap among healthcare professionals, and the potential for quality improvement in patient care.

CHAIRMAN

Enrico **Franceschi**

SCIENTIFIC COMMITTEE

Stefania **Bartolini**

Vincenzo **Di Nunno**

Lidia **Gatto**

FACULTY

Alessandro **Arcidiacono** Bologna

Sofia **Asioli** Bologna

Alfredo **Conti** Bologna

Elisa **D'Angelo** Bologna

Anna Luisa **Di Stefano** Siena

Massimo **Dominici** Modena

Gaetano **Finocchiaro** Milano

Enrico **Franceschi** Bologna

Caterina **Giannini** Rochester, US

Ahmed **Idbaih** Parigi, F

Andrew B. **Lassman** New York, US

Emilie **Le Rhun** Zurigo

Giuseppe **Lombardi** Padova

Giuseppe **Minniti** Roma

Andrea **Pace** Roma

Roberta **Rudà** Torino

Antonio **Silvani** Milano

Matteo **Simonelli** Milano

Carmelo **Sturiale** Bologna

Giovanni **Tallini** Bologna

Alicia **Tosoni** Bologna

Michael **Weller** Zurigo

NEW APPROACHES IN BRAIN TUMORS

09:00	Registration
09:30	Authorities' welcome address E. Franceschi
10:00	INAUGURAL LECTURE Integrated diagnosis in CNS tumors C. Giannini
10:20	SESSION 1 GLIOBLASTOMA Chairs: A. Silvani, E. Le Rhun, C. Sturiale
10:25	State of art G. Lombardi
10:40	Future approaches M. Weller
10:55	Discussion
11:00	SESSION 2 LOW(ER) GRADE GLIOMAS Chairs: M. Weller, A. Lassman, C. Giannini
11:05	The biological landscape of lower grade gliomas S. Asioli
11:20	The era of targeting IDH mutations: repositioning of treatments E. Franceschi
11:35	Discussion
11:40	TRANSATLANTIC LECTURE Progress and priorities in brain tumors: recent results and novel designs from NRG Oncology and other large networks A. Lassman
12:00	Lunch
13:00	SPECIAL SESSION Fondazione scienze neurologiche di Bologna A. Arcidiacono
13:15	SESSION 3 AGNOSTIC APPROACHES FOR BRAIN TUMORS & SPECIAL POPULATIONS Chairs: A. Pace, G. Tallini
13:20	The role of HRD in gliomas: what's next? M. Simonelli
13:35	Special populations : BRAF mutant tumors A. Tosoni
13:50	Special populations: NTRK inhibition A. Silvani
14:05	Special populations: H3 altered DMGs and DHGs E. Le Rhun
14:20	Special populations: FGFR altered tumors A. Di Stefano
14:30	Discussion
14:45	SESSION 4 MORE THAN DRUGS Chairs: A. Conti, E. D'Angelo, M. Dominici
14:50	Opening the BBB: a new model for improving drug delivery? A. Ibdaih
15:05	Tumor treating fields: 12 years later R. Rudà
15:20	Radiotherapy advances G. Minniti
15:35	Immunotherapy, Vaccines and Cellular therapies G. Finocchiaro
15:50	Discussion
15:55	SESSION 5 ROUND TABLE OF THE EMILIA ROMAGNA REGION ONCOLOGY NETWORK FOR BRAIN TUMORS REPRESENTATIVES OF EACH REGIONAL BRAIN TUMOR BOARD TBD
16:55	Closing E. Franceschi